Merrill Lynch Stick to The Buy Rating of theirs for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, which is approximately 9.11 % above the existing share price of $76.07.

Cherny expects CVS Health Corp to submit earnings per share (EPS) of $0.93 for the first quarter of 2021.

The current opinion among eleven TipRanks analysts is for a moderate Buy rating of shares in CVS Health, with an average price goal of $84.

The analysts price targets range from a high of hundred one dolars to a low of sixty one dolars.

In the newest earnings report of its, released on 09/30/2020, the company found a quarterly revenue of $67.06 billion and a net gain of $3.25 billion. The company’s market cap is $99.57 billion.

According to TipRanks.com, Merrill Lynch analyst Michael Cherny is now ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 11.5 % along with a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment extends pharmacy benefit management solutions. The Long or retail Term Care segment includes offering of prescription medications and assortment of general merchandise.

The Health Care Benefits segment offers traditional, consumer-directed and voluntary health insurance products and similar services, including medical, pharmacy, dental, behavioural health, medical management capabilities. The Corporate segment involves in offering administrative services and management. The company was created by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.

Leave a comment